GT Biopharma Inc. Common Stock (GTBP)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

GT Biopharma is a clinical-stage immuno-oncology company with no reported revenue in any of the filed periods I see. Its financial history is that of a development-stage venture: a net loss of $7.6M in fiscal year 2023 (period ended 2023-12-31), $13.2M in fiscal year 2024 (period ended 2024-12-31), and $28.4M in fiscal year 2025 (period ended 2025-12-31). More recently, it lost $2.8M in fiscal Q1 2026 (quarter ended 2026-03-31) and $4.5M in fiscal Q2 2026 (quarter ended 2026-06-30). One quarter, fiscal Q3 2025 (quarter ended 2025-09-30), showed $8.3M of net income, but that was swamped by a $30.2M loss in fiscal Q2 2025 (quarter ended 2025-06-30) and the full-year fiscal 2025 loss. Free cash flow is negative $13.2M on a trailing basis, a -4.5% FCF yield per FairStock, so the company consumes cash. The FairStock metrics underscore fragility: Piotroski F-Score 1/9 and Altman Z-Score -28.07, with a FairStock score of 28/100. At the 2026-10-13 close of $6.50, P/B is 3.25 and P/E is -0.04 because there are no earnings. The 52-week range of $0.22 to $11.98 shows speculative swings. There is no durable moat—no commercial product, no revenue, and no profits—only early Phase 1 candidates. Competitive advantage in biotech can come from data and patents, but I cannot verify either from these figures. Growth is essentially cash burn and trial progress. Graham would demand a margin of safety; here, value depends almost entirely on future scientific success, not on present financial reality. I would watch trial data, cash needs, and any financing, not the stock price.

In plain English: GT Biopharma is a biotech company that is still testing experimental immune-oncology medicines and has not yet sold any products. It has lost money in each of the last four years and is using cash, so the underlying business looks weak and unproven. At $6.50 a share (close on 2026-10-13), it does not look cheap based on current financial numbers; the price depends heavily on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer